{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T23:21:51Z","timestamp":1793316111578,"version":"4.5.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T00:00:00Z","timestamp":1753833600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T00:00:00Z","timestamp":1753833600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"DOI":"10.1186\/s12883-025-04323-0","type":"journal-article","created":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T08:51:59Z","timestamp":1753865519000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Efficacy and safety of levetiracetam for pediatric convulsive status epilepticus in emergency settings: a systematic review and meta-analysis"],"prefix":"10.1186","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7278-2289","authenticated-orcid":false,"given":"Mohammed","family":"Alsabri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah Makram","family":"Elsayed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-4273-0827","authenticated-orcid":false,"given":"Shree","family":"Rath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamza A.","family":"Abdul-Hafez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dina Essam","family":"Abo-elnour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Kurian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,30]]},"reference":[{"issue":"10","key":"4323_CR1","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1111\/epi.13121","volume":"56","author":"E Trinka","year":"2015","unstructured":"Trinka E, Cock H, Hesdorffer D, Rossetti AO, Scheffer IE, Shinnar S, et al. A definition and classification of status epilepticus\u2013Report of the ILAE task force on classification of status epilepticus. Epilepsia. 2015;56(10):1515\u201323.","journal-title":"Epilepsia"},{"issue":"9971","key":"4323_CR2","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1016\/S0140-6736(14)60456-6","volume":"385","author":"SL Mosh\u00e9","year":"2015","unstructured":"Mosh\u00e9 SL, Perucca E, Ryvlin P, Tomson T. Epilepsy: new advances. Lancet. 2015;385(9971):884\u201398.","journal-title":"Lancet"},{"issue":"22","key":"4323_CR3","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1056\/NEJMe1913775","volume":"381","author":"PE Smith","year":"2019","unstructured":"Smith PE. Management of established status epilepticus. N Engl J Med. 2019;381(22):2171\u20132.","journal-title":"N Engl J Med"},{"issue":"5","key":"4323_CR4","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1111\/epi.14729","volume":"60","author":"S Schubert-Bast","year":"2019","unstructured":"Schubert-Bast S, Z\u00f6llner JP, Ansorge S, Hapfelmeier J, Bonthapally V, Eldar-Lissai A, Rosenow F, Strzelczyk A. Burden and epidemiology of status epilepticus in infants, children, and adolescents: A population-based study on German health insurance data. Epilepsia. 2019;60(5):911\u201320. https:\/\/doi.org\/10.1111\/epi.14729. Epub 2019 Apr 13. PMID: 30980677.","journal-title":"Epilepsia"},{"issue":"1","key":"4323_CR5","doi-asserted-by":"publisher","first-page":"48","DOI":"10.5698\/1535-7597-16.1.48","volume":"16","author":"T Glauser","year":"2016","unstructured":"Glauser T, Shinnar S, Gloss D, Alldredge B, Arya R, Bainbridge J, et al. Evidence-Based guideline: treatment of convulsive status epilepticus in children and adults: report of the guideline committee of the American epilepsy society. Epilepsy Currents. 2016;16(1):48\u201361.","journal-title":"Epilepsy Currents"},{"issue":"16","key":"4323_CR6","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1001\/jama.2014.2625","volume":"311","author":"JM Chamberlain","year":"2014","unstructured":"Chamberlain JM, Okada P, Holsti M, Mahajan P, Brown KM, Vance C, et al. Lorazepam vs diazepam for pediatric status epilepticus: a randomized clinical trial. JAMA. 2014;311(16):1652\u201360.","journal-title":"JAMA"},{"issue":"7","key":"4323_CR7","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1056\/NEJMoa1107494","volume":"366","author":"R Silbergleit","year":"2012","unstructured":"Silbergleit R, Durkalski V, Lowenstein D, Conwit R, Pancioli A, Palesch Y, et al. Intramuscular versus intravenous therapy for prehospital status epilepticus. N Engl J Med. 2012;366(7):591\u2013600.","journal-title":"N Engl J Med"},{"issue":"9","key":"4323_CR8","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1007\/s40263-022-00940-2","volume":"36","author":"R Kienitz","year":"2022","unstructured":"Kienitz R, Kay L, Beuchat I, Gelhard S, von Brauchitsch S, Mann C, Lucaciu A, Sch\u00e4fer JH, Siebenbrodt K, Z\u00f6llner JP, Schubert-Bast S, Rosenow F, Strzelczyk A, Willems LM. Benzodiazepines in the management of seizures and status epilepticus: A review of routes of delivery, pharmacokinetics, efficacy, and tolerability. CNS Drugs. 2022;36(9):951\u201375. https:\/\/doi.org\/10.1007\/s40263-022-00940-2. Epub 2022 Aug 16. PMID: 35971024; PMCID: PMC9477921.","journal-title":"CNS Drugs"},{"key":"4323_CR9","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.seizure.2018.01.025","volume":"56","author":"J Furyk","year":"2018","unstructured":"Furyk J, Ray R, Watt K, Dalziel SR, Oakely E, Mackay M, et al. Consensus research priorities for paediatric status epilepticus: A Delphi study of health consumers, researchers and clinicians. Seizure. 2018;56:104\u20139.","journal-title":"Seizure"},{"key":"4323_CR10","doi-asserted-by":"publisher","first-page":"107289","DOI":"10.1016\/j.yebeh.2020.107289","volume":"111","author":"GE Besli","year":"2020","unstructured":"Besli GE, Yuksel Karatoprak E, Yilmaz S. Efficacy and safety profile of intravenous Levetiracetam versus phenytoin in convulsive status epilepticus and acute repetitive seizures in children. Epilepsy Behav. 2020;111:107289.","journal-title":"Epilepsy Behav"},{"key":"4323_CR11","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.","journal-title":"BMJ"},{"key":"4323_CR12","doi-asserted-by":"publisher","unstructured":"Higgins JPT, Thomas J, Chandler J, Cumpston M, LiT, Page MJ, et al., editors. Cochrane handbook for systematic reviews of interventions. 1st ed. Wiley; 2019. https:\/\/doi.org\/10.1002\/9781119536604.","DOI":"10.1002\/9781119536604"},{"issue":"10231","key":"4323_CR13","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1016\/S0140-6736(20)30611-5","volume":"395","author":"JM Chamberlain","year":"2020","unstructured":"Chamberlain JM, Kapur J, Shinnar S, Elm J, Holsti M, Babcock L, et al. Efficacy of levetiracetam, fosphenytoin, and valproate for established status epilepticus by age group (ESETT): a double-blind, responsive-adaptive, randomised controlled trial. Lancet. 2020;395(10231):1217\u201324.","journal-title":"Lancet"},{"issue":"10186","key":"4323_CR14","doi-asserted-by":"publisher","first-page":"2135","DOI":"10.1016\/S0140-6736(19)30722-6","volume":"393","author":"SR Dalziel","year":"2019","unstructured":"Dalziel SR, Borland ML, Furyk J, Bonisch M, Neutze J, Donath S, et al. Levetiracetam versus phenytoin for second-line treatment of convulsive status epilepticus in children (ConSEPT): an open-label, multicentre, randomised controlled trial. Lancet. 2019;393(10186):2135\u201345.","journal-title":"Lancet"},{"issue":"3","key":"4323_CR15","doi-asserted-by":"publisher","first-page":"252","DOI":"10.4103\/jpn.JPN_109_19","volume":"15","author":"A Handral","year":"2020","unstructured":"Handral A, Veerappa BG, Gowda VK, Shivappa SK, Benakappa N, Benakappa A. Levetiracetam versus fosphenytoin in pediatric convulsive status epilepticus: A randomized controlled trial. J Pediatr Neurosci. 2020;15(3):252\u20136.","journal-title":"J Pediatr Neurosci"},{"issue":"8","key":"4323_CR16","doi-asserted-by":"publisher","first-page":"3368","DOI":"10.4103\/jfmpc.jfmpc_1747_23","volume":"13","author":"M Kartek","year":"2024","unstructured":"Kartek M, Kannan A, Anand V, Sahoo MR. Intravenous Levetiracetam versus intravenous phenytoin as second line treatment in pediatric convulsive status epilepticus- open label randomized controlled trial. J Family Med Prim Care. 2024;13(8):3368\u201373.","journal-title":"J Family Med Prim Care"},{"issue":"7","key":"4323_CR17","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1007\/s00381-022-05543-2","volume":"38","author":"MT Kole","year":"2022","unstructured":"Kole MT, Sager SG, Zeynel H, Cag Y, Akin Y. Efficacy of intravenous Levetiracetam versus phenytoin in convulsive status epilepticus and acute repetitive seizures in children. Childs Nerv Syst. 2022;38(7):1357\u201364.","journal-title":"Childs Nerv Syst"},{"issue":"10186","key":"4323_CR18","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1016\/S0140-6736(19)30724-X","volume":"393","author":"MD Lyttle","year":"2019","unstructured":"Lyttle MD, Rainford NEA, Gamble C, Messahel S, Humphreys A, Hickey H, et al. Levetiracetam versus phenytoin for second-line treatment of paediatric convulsive status epilepticus (EcLiPSE): a multicentre, open-label, randomised trial. Lancet. 2019;393(10186):2125\u201334.","journal-title":"Lancet"},{"issue":"3","key":"4323_CR19","doi-asserted-by":"publisher","first-page":"410","DOI":"10.55519\/JAMC-03-11897","volume":"35","author":"B Naeem","year":"2023","unstructured":"Naeem B, Ashfaq M, Qureshi MA. Efficacy of Levetiracetam versus phenytoin as A Second-Line antiepileptic drug in the management of Benzodiazepine-Refractory status epilepticus among children. J Ayub Med Coll Abbottabad. 2023;35(3):410\u20134.","journal-title":"J Ayub Med Coll Abbottabad"},{"issue":"7","key":"4323_CR20","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1007\/s12098-020-03221-2","volume":"87","author":"S Nalisetty","year":"2020","unstructured":"Nalisetty S, Kandasamy S, Sridharan B, Vijayakumar V, Sangaralingam T, Krishnamoorthi N. Clinical effectiveness of Levetiracetam compared to fosphenytoin in the treatment of benzodiazepine refractory convulsive status epilepticus. Indian J Pediatr. 2020;87(7):512\u20139.","journal-title":"Indian J Pediatr"},{"issue":"2","key":"4323_CR21","doi-asserted-by":"publisher","first-page":"69","DOI":"10.14581\/jer.20011","volume":"10","author":"M Nazir","year":"2020","unstructured":"Nazir M, Tarray RA, Asimi R, Syed WA. Comparative efficacy of IV phenytoin, IV valproate, and IV Levetiracetam in childhood status epilepticus. J Epilepsy Res. 2020;10(2):69\u201373.","journal-title":"J Epilepsy Res"},{"issue":"4","key":"4323_CR22","doi-asserted-by":"publisher","first-page":"468","DOI":"10.3988\/jcn.2019.15.4.468","volume":"15","author":"N Noureen","year":"2019","unstructured":"Noureen N, Khan S, Khursheed A, Iqbal I, Maryam M, Sharib SM, et al. Clinical efficacy and safety of injectable Levetiracetam versus phenytoin as Second-Line therapy in the management of generalized convulsive status epilepticus in children: an Open-Label randomized controlled trial. J Clin Neurol. 2019;15(4):468\u201372.","journal-title":"J Clin Neurol"},{"issue":"2","key":"4323_CR23","doi-asserted-by":"publisher","first-page":"158","DOI":"10.4103\/JPN.JPN_126_17","volume":"13","author":"K Singh","year":"2018","unstructured":"Singh K, Aggarwal A, Faridi MMA, Sharma S. IV Levetiracetam versus IV phenytoin in childhood seizures: A randomized controlled trial. J Pediatr Neurosci. 2018;13(2):158\u201364.","journal-title":"J Pediatr Neurosci"},{"issue":"3","key":"4323_CR24","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1007\/s13312-020-1755-4","volume":"57","author":"V Vignesh","year":"2020","unstructured":"Vignesh V, Rameshkumar R, Mahadevan S. Comparison of phenytoin, valproate and Levetiracetam in pediatric convulsive status epilepticus: A randomized Double-blind controlled clinical trial. Indian Pediatr. 2020;57(3):222\u20137.","journal-title":"Indian Pediatr"},{"issue":"3","key":"4323_CR25","doi-asserted-by":"publisher","first-page":"779","DOI":"10.51253\/pafmj.v72i3.7651","volume":"72","author":"S Zaman","year":"2022","unstructured":"Zaman S, Shuaib A, Shah SA, Zahid M, Khan QUZ, Murad M. Outcome of intravenous Levetiracetam versus intravenous phenytoin in management of children with status epilepticus. Pakistan Armed Forces Med J. 2022;72(3):779\u201382.","journal-title":"Pakistan Armed Forces Med J"},{"issue":"22","key":"4323_CR26","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1056\/NEJMoa1905795","volume":"381","author":"J Kapur","year":"2019","unstructured":"Kapur J, Elm J, Chamberlain JM, et al. Randomized trial of three anticonvulsant medications for status epilepticus. N Engl J Med. 2019;381(22):2103\u201313.","journal-title":"N Engl J Med"},{"key":"4323_CR27","doi-asserted-by":"publisher","unstructured":"Angurana SK, Suthar R. Efficacy and safety of levetiracetam vs. phenytoinas second line antiseizure medication for pediatric convulsive status epilepticus: a systematic review and meta-analysis of randomized controlled trials. J Trop Pediatr. 2021;67(2):fmab014. https:\/\/doi.org\/10.1093\/tropej\/fmab014.","DOI":"10.1093\/tropej\/fmab014"},{"key":"4323_CR28","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.seizure.2021.07.012","volume":"91","author":"Y Feng","year":"2021","unstructured":"Feng Y, Chen Y, Jia Y, Wang Z, Wang X, Jiang L, et al. Efficacy and safety of Levetiracetam versus (fos)phenytoin for second-line treatment of epilepticus: a meta-analysis of latest randomized controlled trials. Seizure. 2021;91:339\u201345.","journal-title":"Seizure"},{"key":"4323_CR29","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1111\/j.1528-1167.2008.01444.x","volume":"49","author":"AT Berg","year":"2008","unstructured":"Berg AT. Risk of recurrence after a first unprovoked seizure. Epilepsia. 2008;49:13\u20138.","journal-title":"Epilepsia"},{"key":"4323_CR30","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.seizure.2017.02.006","volume":"49","author":"S Rizvi","year":"2017","unstructured":"Rizvi S, Ladino LD, Hernandez-Ronquillo L, T\u00e9llez-Zenteno JF. Epidemiology of early stages of epilepsy: risk of seizure recurrence after a first seizure. Seizure. 2017;49:46\u201353.","journal-title":"Seizure"},{"key":"4323_CR31","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1097\/MOP.0000000000000154","volume":"26","author":"NS Abend","year":"2014","unstructured":"Abend NS, Loddenkemper T. Pediatric status epilepticus management. Curr Opin Pediatr. 2014;26:668\u201374. https:\/\/doi.org\/10.1097\/MOP.0000000000000154.","journal-title":"Curr Opin Pediatr"},{"key":"4323_CR32","doi-asserted-by":"publisher","first-page":"146","DOI":"10.17712\/nsj.2017.2.20170093","volume":"22","author":"FA Bashiri","year":"2017","unstructured":"Bashiri FA, Hamad MH, Amer YS, Abouelkheir MM, Mohamed S, Kentab AY, et al. Management of convulsive status epilepticus in children: an adapted clinical practice guideline for pediatricians in Saudi Arabia. Neurosciences. 2017;22:146\u201355.","journal-title":"Neurosciences"},{"key":"4323_CR33","doi-asserted-by":"crossref","unstructured":"Deshpande LS, DeLorenzo RJ. Mechanisms of levetiracetam in the control of status epilepticus and epilepsy. Front Neurol. 2014;5.","DOI":"10.3389\/fneur.2014.00011"},{"key":"4323_CR34","doi-asserted-by":"publisher","first-page":"39","DOI":"10.4103\/ijp.IJP_692_17","volume":"50","author":"R Bansal","year":"2018","unstructured":"Bansal R, Suri V, Chopra S, Aggarwal N, Sikka P, Saha S, et al. Levetiracetam use during pregnancy in women with epilepsy: preliminary observations from a tertiary care center in Northern India. Indian J Pharmacol. 2018;50:39.","journal-title":"Indian J Pharmacol"},{"key":"4323_CR35","doi-asserted-by":"crossref","unstructured":"Nakamura K, Ohbe H, Matsui H, Takahashi Y, Marushima A, Inoue Y, et al. Levetiracetam vs. fosphenytoin for second-line treatment of status epilepticus: propensity score matching analysis using a nationwide inpatient database. Front Neurol. 2020;11.","DOI":"10.3389\/fneur.2020.00615"},{"key":"4323_CR36","doi-asserted-by":"publisher","first-page":"e480","DOI":"10.1097\/PCC.0000000000002703","volume":"22","author":"JA Klowak","year":"2021","unstructured":"Klowak JA, Hewitt M, Catenacci V, Duffett M, Rochwerg B, Jones K, et al. Levetiracetam versus phenytoin or fosphenytoin for Second-Line treatment of pediatric status epilepticus: A Meta-Analysis. Pediatr Crit Care Med. 2021;22:e480\u201391.","journal-title":"Pediatr Crit Care Med"},{"key":"4323_CR37","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/j.seizure.2014.06.004","volume":"23","author":"E Halma","year":"2014","unstructured":"Halma E, De Louw AJA, Klinkenberg S, Aldenkamp AP, IJff DM, Majoie M. Behavioral side-effects of Levetiracetam in children with epilepsy: A systematic review. Seizure. 2014;23:685\u201391.","journal-title":"Seizure"},{"key":"4323_CR38","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.seizure.2020.05.017","volume":"80","author":"K Nakamura","year":"2020","unstructured":"Nakamura K, Ohbe H, Matsui H, et al. Phenytoin versus fosphenytoin for second-line treatment of status epilepticus: propensity score matching analysis using a nationwide inpatient database. Seizure. 2020;80:124\u201330. https:\/\/doi.org\/10.1016\/j.seizure.2020.05.017.","journal-title":"Seizure"},{"issue":"4","key":"4323_CR39","doi-asserted-by":"publisher","first-page":"326","DOI":"10.4103\/0974-2700.70749","volume":"3","author":"LV Downey","year":"2010","unstructured":"Downey LV, Zun L. Pain management in the emergency department and its relationship to patient satisfaction. J Emergencies Trauma Shock. 2010;3(4):326. https:\/\/doi.org\/10.4103\/0974-2700.70749.","journal-title":"J Emergencies Trauma Shock"},{"key":"4323_CR40","doi-asserted-by":"publisher","unstructured":"Jost J, Raharivelo A, Ratsimbazafy V, et al. Availability and cost of major and first-line antiepileptic drugs: a comprehensive evaluation in the capital of Madagascar. SpringerPlus. 2016;5(1). https:\/\/doi.org\/10.1186\/s40064-016-3409-5.","DOI":"10.1186\/s40064-016-3409-5"},{"issue":"11","key":"4323_CR41","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1007\/s40263-023-01049-w","volume":"37","author":"L Purwien","year":"2023","unstructured":"Purwien L, Schubert-Bast S, Kieslich M, et al. Trends and differences in status epilepticus treatment of children and adults over 10 years: A comparative study of medical records (2012\u20132021) from a university hospital in Germany. CNS Drugs. 2023;37(11):993\u20131008. https:\/\/doi.org\/10.1007\/s40263-023-01049-w.","journal-title":"CNS Drugs"},{"key":"4323_CR42","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.yebeh.2017.11.024","volume":"79","author":"F Sanmart\u00ed-Vilaplana","year":"2017","unstructured":"Sanmart\u00ed-Vilaplana F, D\u00edaz-G\u00f3mez A. The effectiveness and safety of lacosamide in children with epilepsy in a clinical practice setting. Epilepsy Behav. 2017;79:130\u20137. https:\/\/doi.org\/10.1016\/j.yebeh.2017.11.024.","journal-title":"Epilepsy Behav"},{"key":"4323_CR43","doi-asserted-by":"publisher","unstructured":"Farkas V, Steinborn B, Flamini JR, et al. Efficacy and tolerability of adjunctive lacosamide in pediatric patients with focal seizures. Neurology. 2019;93(12). https:\/\/doi.org\/10.1212\/wnl.0000000000008126.","DOI":"10.1212\/wnl.0000000000008126"}],"updated-by":[{"DOI":"10.1186\/s12883-025-04507-8","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T00:00:00Z","timestamp":1762905600000}}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-025-04323-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12883-025-04323-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-025-04323-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T06:33:17Z","timestamp":1763015597000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcneurol.biomedcentral.com\/articles\/10.1186\/s12883-025-04323-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,30]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4323"],"URL":"https:\/\/doi.org\/10.1186\/s12883-025-04323-0","relation":{},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,30]]},"assertion":[{"value":"2 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2025","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised: the authors reported a misspelled author name \"Elizabeth Kuriam\". The correct name should be \"Elizabeth Kurian\". Also, affiliations 2, 7 and 8 are the same. Mohammed Alsabri and Elizabeth Kurian\u2019s affiliation are updated.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2025","order":8,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":9,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s12883-025-04507-8","URL":"https:\/\/doi.org\/10.1186\/s12883-025-04507-8","order":11,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"309"}}